MAPT and early-onset autosomal dominant Alzheimer disease: According to Bjerke and Engelborghs (2018, 1199), there are ‘three core CSF biomarkers for Alzheimer's disease diagnostics, namely, the 42 amino acid long amyloid‐beta peptide [Aβ42], total tau protein, and tau phosphorylated [p‐tau]’.